

REMOVED

\*\*\*

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<  
\*\*\*\*

File 1:ERIC 1966-2003/Sep 11  
(c) format only 2003 The Dialog Corporation

Set Items Description

--- -----

Cost is in DialUnits

? b 410

12sep03 14:33:11 User208760 Session D2366.1  
\$0.32 0.092 DialUnits File1  
\$0.32 Estimated cost File1  
\$0.32 Estimated cost this search  
\$0.32 Estimated total session cost 0.092 DialUnits

File 410:Chronolog(R) 1981-2003/Aug  
(c) 2003 The Dialog Corporation

Set Items Description

--- -----

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

12sep03 14:33:16 User208760 Session D2366.2  
\$0.00 0.072 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.01 TELNET  
\$0.01 Estimated cost this search  
\$0.33 Estimated total session cost 0.164 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2003/Sep W1  
(c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Sep W1  
(c) 2003 Elsevier Science B.V.

File 155:MEDLINE(R) 1966-2003/Sep W1  
(c) format only 2003 The Dialog Corp.

\*File 155: Medline has been reloaded and accession numbers have  
changed. Please see HELP NEWS 155.

File 399:CA SEARCH(R) 1967-2003/UD=13911  
(c) 2003 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

--- -----

? e au=dumoutier

Ref	Items	Index-term
E1	1	AU=DUMOUTHIER N.
E2	1	AU=DUMOUTHIER, N.
E3	0	*AU=DUMOUTIER
E4	2	AU=DUMOUTIER A
E5	11	AU=DUMOUTIER L
E6	12	AU=DUMOUTIER L.
E7	20	AU=DUMOUTIER LAURE
E8	8	AU=DUMOUTIER N
E9	9	AU=DUMOUTIER N.

E10 6 AU=DUMOUTIER NADINE  
 E11 2 AU=DUMOUTIER, L.  
 E12 21 AU=DUMOUTIER, LAURE

Enter P or PAGE for more

? p

Ref	Items	Index-term
E13	13	AU=DUMOUTIER, N.
E14	3	AU=DUMOUTIER, NADINE
E15	1	AU=DUMOUX P
E16	2	AU=DUMOUX, PIERRE
E17	1	AU=DUMOV A A
E18	1	AU=DUMOV A M
E19	1	AU=DUMOV G
E20	4	AU=DUMOV, A. M.
E21	2	AU=DUMOV, B. I.
E22	1	AU=DUMOV, D. I.
E23	1	AU=DUMOV, S. I.
E24	21	AU=DUMOV, S. N.

Enter P or PAGE for more

? s e5-e12

11 AU=DUMOUTIER L  
 12 AU=DUMOUTIER L.  
 20 AU=DUMOUTIER LAURE  
 8 AU=DUMOUTIER N  
 9 AU=DUMOUTIER N.  
 6 AU=DUMOUTIER NADINE  
 2 AU=DUMOUTIER, L.  
 21 AU=DUMOUTIER, LAURE

S1 89 E5-E12

? s s1 and (t(w)cell(w)inducible or tif?)

Processing

89 S1  
 4539746 T  
 7114250 CELL  
 135929 INDUCIBLE  
 27 T(W)CELL(W)INDUCIBLE  
 7356 TIF?

S2 25 S1 AND (T(W)CELL(W)INDUCIBLE OR TIF?)

? rd s2

...completed examining records

S3 13 RD S2 (unique items)

? t s3/7/all

3/7/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2003 BIOSIS. All rts. reserv.

13862754 BIOSIS NO.: 200200491575  
 Crystal structure of recombinant human interleukin-22.  
 AUTHOR: Nagem Ronaldo Alves Pinto; Colau Didier; **Dumoutier Laure**;  
 Renauld Jean-Christophe; Ogata Craig; Polikarpov Igor(a  
 AUTHOR ADDRESS: (a)Laboratorio Nacional de Luz Sincrotron, Caixa Postal  
 6192, CEP 13084-971, Campinas, SP\*\*Brazil E-Mail:  
 ipolikarpov@if.sc.usp.br  
 JOURNAL: Structure (Cambridge) 10 (8):p1051-1062 August, 2002  
 MEDIUM: print  
 ISSN: 0969-2126  
 DOCUMENT TYPE: Article  
 RECORD TYPE: Abstract  
 LANGUAGE: English

ABSTRACT: Interleukin-22 (IL-10-related T cell-derived inducible factor/IL-TIF/IL-22) is a novel cytokine belonging to the IL-10 family. Recombinant human IL-22 (hIL-22) was found to activate the signal transducers and activators of transcription factors 1 and 3 as well as acute phase reactants in several hepatoma cell lines, suggesting its involvement in the inflammatory response. The crystallographic structure of recombinant hIL-22 has been solved at 2.0 ANG resolution using the SIRAS method. Contrary to IL-10, the hIL-22 dimer does not present an interpenetration of the secondary-structure elements belonging to the two distinct polypeptide chains but results from interface interactions between monomers. Structural differences between these two cytokines, revealed by the crystallographic studies, clearly indicate that, while a homodimer of IL-10 is required for signaling, hIL-22 most probably interacts with its receptor as a monomer.

3/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13769960 BIOSIS NO.: 200200398781  
Viral and cellular interleukin-10 (IL-10)-related cytokines: From structures to functions.  
AUTHOR: **Dumoutier Laure**; Renauld Jean-Christophe(a)  
AUTHOR ADDRESS: (a)Ludwig Institute for Cancer Research, Avenue Hippocrate, 74, UCL 74 59, B-1200, Brussels\*\*Belgium E-Mail: jean-christophe.renauld@bru.licr.org  
JOURNAL: European Cytokine Network 13 (1):p5-15 Jan.-March, 2002  
MEDIUM: print  
ISSN: 1148-5493  
DOCUMENT TYPE: Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: The anti-inflammatory and immunosuppressive activities of IL-10 have been extensively studied during the last 10 years. More recently a series of new cytokines, structurally related to IL-10, were described. This family includes mda-7, IL-19, IL-20, IL-TIF/IL-22, and AK155. Most of the biological functions of these cytokines remain to be unraveled but new data are coming out steadily. Although none of these "IL-10 homologs" mimics IL-10 activities, they are likely to be involved in inflammatory processes as well. mda-7, IL-19 and IL-20 form a subfamily within IL-10 homologs, based on conserved amino acid sequences, and on the use of shared receptor complexes. Functional studies have stressed the potential suppressing activity of mda-7 on tumor growth. As for IL-20, its overexpression in transgenic mice led to skin abnormalities, reminiscent of psoriatic lesions in humans. IL-TIF/IL-22 is a Th1 cytokine, and was shown to upregulate the acute phase reactant production by liver cells. Finally, for AK155, originally described as a gene induced upon T cell transformation by Herpes-virus saimiri, functional data are still lacking to determine its biological activities.

3/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13611722 BIOSIS NO.: 200200240543  
Isolated nucleic acid molecules which encode **T cell inducible factors (TIFs)**, the proteins encoded, and uses therefor.  
AUTHOR: **Dumoutier Laure**(a); Louhed Jamila; Renauld Jean-Christophe  
AUTHOR ADDRESS: (a)Brussels\*\*Belgium

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1256 (3):pNo Pagination Mar. 19, 2002  
MEDIUM: e-file  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as **T cell inducible** factors.

3/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13505673 BIOSIS NO.: 200200134494  
Isolated nucleic acid molecules which encode **T cell inducible** factors (**TIFS**), the proteins encoded, and uses thereof.

AUTHOR: **Dumoutier Laure**(a); Louhed Jamila; Renauld Jean-Christophe  
AUTHOR ADDRESS: (a)Brussels\*\*Belgium  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1253 (3):pNo Pagination Dec. 18, 2001  
MEDIUM: e-file  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as **T cell inducible** factors.

3/7/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

12714780 BIOSIS NO.: 200000468282  
IL-**TIF** induces acute phase reactant production by hepatocytes through IL-10Rbeta.  
AUTHOR: **Dumoutier L**(a); Van Roost E(a); Colau D(a); Renauld J-C(a)  
AUTHOR ADDRESS: (a)Brussels Branch, Ludwig Institute for Cancer Research, Brussels\*\*Belgium  
JOURNAL: Immunology Letters 73 (2-3):p261 September, 2000  
MEDIUM: print  
CONFERENCE/MEETING: 24th European Immunology Meeting of the European Federation of Immunological Societies (EFIS) Poznan, Poland September 23-26, 2000  
SPONSOR: European Federation of Immunological Societies  
ISSN: 0165-2478  
RECORD TYPE: Citation  
LANGUAGE: English  
SUMMARY LANGUAGE: English

3/7/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

12713983 BIOSIS NO.: 200000467485  
Cloning and characterization of mouse and human **TIF**, a new  
IL-1-related cytokine.  
AUTHOR: **Dumoutier** L(a); Ameye G(a); Michaux L(a); Renauld J-C(a)  
AUTHOR ADDRESS: (a)Ludwig Institute for Cancer Research, Brussels Branch,  
Cliniques Univesitaires St-Luc, B-1200, Brussels\*\*Belgium  
JOURNAL: Cytokine 11 (11):p969 Nov., 1999  
MEDIUM: print  
CONFERENCE/MEETING: Seventh Annual Conference of the International Cytokine  
Society Hilton Head, South Carolina, USA December 5-9, 1999  
SPONSOR: The International Cytokine Society  
ISSN: 1043-4666  
RECORD TYPE: Citation  
LANGUAGE: English  
SUMMARY LANGUAGE: English

3/7/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

12687035 BIOSIS NO.: 200000440537  
Human interleukin-10-related T cell-derived inducible factor: Molecular  
cloning and functional characterization as an hepatocyte-stimulating  
factor.  
AUTHOR: **Dumoutier Laure**; Van Roost Emiel; Colau Didier; Renauld  
Jean-Christophe(a)  
AUTHOR ADDRESS: (a)Brussels Branch and Experimental Medicine Unit, Ludwig  
Institute for Cancer Research, Christian de Duve Institute of Cellular  
Pathology, Universite Catholique de Louvain, Avenue Hippocrate 74, B1200,  
Brussels\*\*Belgium  
JOURNAL: Proceedings of the National Academy of Sciences of the United  
States of America 97 (18):p10144-10149 August 29, 2000  
MEDIUM: print  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: IL-10-related T cell-derived inducible factor (IL-**TIF** or  
IL-21) is a new cytokine structurally related to IL-10 and originally  
identified in the mouse as a gene induced by IL-9 in T cells and mast  
cells. Here, we report the cloning of the human IL-**TIF** cDNA, which  
shares 79% amino acid identity with mouse IL-**TIF** and 25% identity  
with human IL-10. Recombinant human IL-**TIF** was found to activate  
signal transducer and activator of transcription factors-1 and -3 in  
several hepatoma cell lines. IL-**TIF** stimulation of HepG2 human  
hepatoma cells up-regulated the production of acute phase reactants such  
as serum amyloid A, alpha1-antichymotrypsin, and haptoglobin. Although  
IL-10 and IL-**TIF** have distinct activities, antibodies directed  
against the beta chain of the IL-10 receptor blocked the induction of  
acute phase reactants by IL-**TIF**, indicating that this chain is a  
common component of the IL-10 and IL-**TIF** receptors. Similar acute  
phase reactant induction was observed in mouse liver upon IL-**TIF**  
injection, and IL-**TIF** expression was found to be rapidly increased  
after lipopolysaccharide (LPS) injection, suggesting that this cytokine  
contributes to the inflammatory response in vivo.

3/7/8 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

10608331 EMBASE No: 2000073611

Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-**TIF**), a novel cytokine structurally related to IL-10 and inducible by IL-9

**Dumoutier L.**; Louahed J.; Renauld J.-C.

Dr. J.-C. Renauld, Ludwig Institute for Cancer Research, Avenue Hippocrate, 74, B-1200 Brussels Belgium

AUTHOR EMAIL: renauld@licr.ucl.ac.be

Journal of Immunology ( J. IMMUNOL. ) (United States) 15 FEB 2000, 164/4 (1814-1819)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 23

IL-9 is a Th2 cytokine active on various cell types such as T and B lymphocytes, mast cells, and eosinophils, and potentially involved in allergy and asthma. To understand better the molecular mechanisms underlying the activity of this cytokine, we used a cDNA subtraction method to identify genes specifically induced by IL-9 in mouse T cells. One of the IL-9- regulated genes isolated by this approach turned out to encode a 180-amino acid long protein, including a potential signal peptide, and showing 22% amino acid identity with IL-10. This protein, designated IL-10-related T cell-derived inducible factor (IL-**TIF**), is induced by IL-9 in thymic lymphomas, T cells, and mast cells, and by lectins in freshly isolated splenocytes. Experiments concerning the mechanism regulating IL-**TIF** expression in T cells indicate that IL-9 induction is rapid (within 1 h), does not require protein synthesis, and depends on the activation of the Janus kinase (JAK)-STAT pathway. In vivo, constitutive expression of IL-**TIF** was detected by RT-PCR in thymus and brain, suggesting that the role of this new factor is not restricted to the immune system. Transfection of HEK293 cells with the IL-**TIF** cDNA resulted in the production of a glycosylated protein of about 25 kDa that was found to induce STAT activation in mesangial and neuronal cell lines. Further studies will have to address the possibility that some of the IL-9 activities may be mediated by IL-**TIF**.

3/7/9 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

09508516 21286452 PMID: 11390453

Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22.

**Dumoutier L.**; Lejeune D; Colau D; Renauld J C

Ludwig Institute for Cancer Research, Brussels Branch and the Experimental Medicine Unit, Christian de Duve Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium.

Journal of immunology (Baltimore, Md. - 1950) (United States) Jun 15 2001, 166 (12) p7090-5, ISSN 0022-1767 Journal Code: 2985117R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The class II cytokine receptor family includes the receptors for IFN- $\alpha$ , IFN- $\gamma$ , IL-10, and IL-10-related T cell-derived inducible factor/IL-22. By screening genomic DNA databases, we identified a gene

encoding a protein of 231 aa, showing 33 and 34% amino acid identity with the extracellular domains of the IL-22 receptor and of the IL-20R/cytokine receptor family 2-8, respectively, but lacking the transmembrane and cytoplasmic domains. A lower but significant sequence identity was found with other members of this family such as the IL-10R (29%), cytokine receptor family 2-4/IL-10Rbeta (30%), tissue factor (26%), and the four IFN receptor chains (23-25%). This gene is located on chromosome 6q24, at 35 kb from the IFNGR1 gene, and is expressed in various tissues with maximal expression in breast, lungs, and colon. The recombinant protein was found to bind IL-10-related T cell-derived inducible factor/IL-22, and to inhibit the activity of this cytokine on hepatocytes and intestinal epithelial cells. We propose to name this natural cytokine antagonist IL-22BP for IL-22 binding protein.

Record Date Created: 20010606

Record Date Completed: 20010823

3/7/10 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09312548 21069354 PMID: 11197690

IL-TIF /IL-22: genomic organization and mapping of the human and mouse genes.

Dumoutier L; Van Roost E; Ameye G; Michaux L; Renauld J C

Ludwig Institute for Cancer Research, Brussels Branch, Experimental Medicine Unit, Christian de Duve Institute of Cellular Pathology, Brussels, Belgium.

Genes and immunity (England) Dec 2000, 1 (8) p488-94, ISSN 1466-4879 Journal Code: 100953417

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

IL-TIF is a new cytokine originally identified as a gene induced by IL-9 in murine T lymphocytes, and showing 22% amino acid identity with IL-10. Here, we report the sequence and organization of the mouse and human IL-TIF genes, which both consist of 6 exons spreading over approximately 6 Kb. The IL-TIF gene is a single copy gene in humans, and is located on chromosome 12q15, at 90 Kb from the IFN gamma gene, and at 27 Kb from the AK155 gene, which codes for another IL-10-related cytokine. In the mouse, the IL-TIF gene is located on chromosome 10, also in the same region as the IFN gamma gene. Although it is a single copy gene in BALB/c and DBA/2 mice, the IL-TIF gene is duplicated in other strains such as C57Bl/6, FVB and 129. The two copies, which show 98% nucleotide identity in the coding region, were named IL-TIF alpha and IL-TIF beta. Beside single nucleotide variations, they differ by a 658 nucleotide deletion in IL-TIF beta, including the first non-coding exon and 603 nucleotides from the promoter. A DNA fragment corresponding to this deletion was sufficient to confer IL-9-regulated expression of a luciferase reporter plasmid, suggesting that the IL-TIF beta gene is either differentially regulated, or not expressed at all.

Record Date Created: 20010129

Record Date Completed: 20010426

3/7/11 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136274327 CA: 136(18)274327x PATENT

Protein and cDNA sequences of human soluble interleukin 22 binding protein and uses in drug screening

INVENTOR(AUTHOR): Renauld, Jean-Christophe; Dumoutier, Laure  
LOCATION: USA  
ASSIGNEE: Ludwig Institute for Cancer Research  
PATENT: PCT International ; WO 200224912 A2 DATE: 20020328  
APPLICATION: WO 2001US29576 (20010921) \*US PV234583 (20000922) \*US  
PV245495 (20001103) \*US 919162 (20010731)  
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/12A;  
C12N-005/10B; C12N-005/20B; C12Q-001/68B; C07K-014/715B; C07K-016/18B;  
G01N-033/68B; G01N-033/53B; A61K-038/17B DESIGNATED COUNTRIES: AE; AL; AM;  
AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES;  
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC;  
LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU;  
SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW;  
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW  
; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG  
SECTION:  
CA203003 Biochemical Genetics  
IDENTIFIERS: human interleukin binding protein cDNA sequence  
DESCRIPTORS:  
Antibodies...  
against interleukin 22 binding protein; protein and cDNA sequences of  
human sol. interleukin 22 binding protein and uses in drug screening  
Hybridoma...  
cell; protein and cDNA sequences of human sol. interleukin 22 binding  
protein and uses in drug screening  
Intestine...  
colon, tissue, interleukin 22 binding protein strongly expressed in;  
protein and cDNA sequences of human sol. interleukin 22 binding protein  
and uses in drug screening  
Genetic vectors...  
expressing interleukin 22 binding protein; protein and cDNA sequences  
of human sol. interleukin 22 binding protein and uses in drug screening  
Promoter(genetic element)...  
for expressing interleukin 22 binding protein; protein and cDNA  
sequences of human sol. interleukin 22 binding protein and uses in drug  
screening  
Labels...  
for interleukin 22 binding protein; protein and cDNA sequences of human  
sol. interleukin 22 binding protein and uses in drug screening  
Gene, animal...  
interleukin 22 binding protein; protein and cDNA sequences of human  
sol. interleukin 22 binding protein and uses in drug screening  
Proteins...  
interleukin 22 binding; protein and cDNA sequences of human sol.  
interleukin 22 binding protein and uses in drug screening  
Antibodies...  
monoclonal, against interleukin 22 binding protein; protein and cDNA  
sequences of human sol. interleukin 22 binding protein and uses in drug  
screening  
Drug screening... cDNA sequences... Protein sequences... Human...  
protein and cDNA sequences of human sol. interleukin 22 binding protein  
and uses in drug screening  
Mammary gland... Lung... Stomach...  
tissue, interleukin 22 binding protein strongly expressed in; protein  
and cDNA sequences of human sol. interleukin 22 binding protein and  
uses in drug screening  
Animal cell line...  
transgenic; protein and cDNA sequences of human sol. interleukin 22  
binding protein and uses in drug screening  
Interleukins...  
22, IL-TIF/IL-22, binding protein; protein and cDNA sequences of human  
sol. interleukin 22 binding protein and uses in drug screening



CAS REGISTRY NUMBERS:

406152-12-3P 406152-15-6 amino acid sequence; protein and cDNA sequences of human sol. interleukin 22 binding protein and uses in drug screening  
406152-11-2D 406152-14-5D subfragment is claimed, nucleotide sequence; protein and cDNA sequences of human sol. interleukin 22 binding protein and uses in drug screening  
406152-42-9 406152-43-0 406152-44-1 406152-45-2 406152-46-3  
406152-47-4 406152-48-5 unclaimed nucleotide sequence; protein and cDNA sequences of human sol. interleukin 22 binding protein and uses in drug screening

3/7/12 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136246402 CA: 136(16)246402z PATENT

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin-9 effects

INVENTOR(AUTHOR): Dumoutier, Laure; Louhed, Jamila; Renauld, Jean-Christophe

LOCATION: USA

ASSIGNEE: Ludwig Institute for Cancer Research

PATENT: United States ; US 6359117 B1 DATE: 20020319

APPLICATION: US 354243 (19990716) \*US 178973 (19981026)

PAGES: 23 pp., Cont.-in-part of U.S. Ser. No. 178,973. CODEN: USXXAM

LANGUAGE: English CLASS: 530351000; C07K-014/52A

SECTION:

CA215005 Immunochemistry

IDENTIFIERS: T cell inducible factor TIF cytokine interleukin 9

DESCRIPTORS:

Animal cell line...

A20; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin

Animal cell line...

BCL-1; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleuk

Animal cell line...

BW5147; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleu

Animal cell line...

COS; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin

DNA...

genomic; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interle

T cell(lymphocyte)...

helper cell; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and int

Protein sequences...

homol.; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleu

Chromosome...

human 12, 12q15; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and

Interleukin 9... Protein sequences... DNA sequences... Human... Mouse...  
 Spleen... T cell(lymphocyte)... Mast cell... B cell(lymphocyte)...

Interleukin 2... Interleukin 4... Liver... Kidney... Heart... Brain...  
 Intestine... Thymus gland... Lung... Muscle... Bone marrow... cDNA...

Antibodies...  
 isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin-9 ef

Animal cell line...  
 LI38; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleuki

Animal cell line...  
 MC9; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin

Kidney...  
 mesangium; isolated nucleic acid mols. which encode T cell inducible  
 factors (TIFs), proteins encoded, and uses thereof in prepn. of  
 antibodies and immunogens and in study of STAT activation and inter

Nerve...  
 neuron; isolated nucleic acid mols. which encode T cell inducible  
 factors (TIFs), proteins encoded, and uses thereof in prepn. of  
 antibodies and immunogens and in study of STAT activation and interleu

Transcription factors...  
 STAT1; isolated nucleic acid mols. which encode T cell inducible  
 factors (TIFs), proteins encoded, and uses thereof in prepn. of  
 antibodies and immunogens and in study of STAT activation and interleuk

Transcription factors...  
 STAT3; isolated nucleic acid mols. which encode T cell inducible  
 factors (TIFs), proteins encoded, and uses thereof in prepn. of  
 antibodies and immunogens and in study of STAT activation and interleuk

Transcription factors...  
 STAT5; isolated nucleic acid mols. which encode T cell inducible  
 factors (TIFs), proteins encoded, and uses thereof in prepn. of  
 antibodies and immunogens and in study of STAT activation and interleuk

Cytokines...  
 TIF (T cell inducible factor); isolated nucleic acid mols. which encode  
 T cell inducible factors (TIFs), proteins encoded, and uses thereof in  
 prepn. of antibodies and immunogens and in study of STAT

Cytokines...  
 TIF.alpha. (T cell inducible factor .alpha.); isolated nucleic acid  
 mols. which encode T cell inducible factors (TIFs), proteins encoded,  
 and uses thereof in prepn. of antibodies and immunogens and in

Cytokines...  
 TIF.beta. (T cell inducible factor .beta.); isolated nucleic acid mols.  
 which encode T cell inducible factors (TIFs), proteins encoded, and  
 uses thereof in prepn. of antibodies and immunogens and in s

Animal cell line...  
 TS1; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin

Animal cell line...  
 TS2; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin

Animal cell line...  
 TS3; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin

Animal cell line...  
 TS6; isolated nucleic acid mols. which encode T cell inducible factors  
 (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and  
 immunogens and in study of STAT activation and interleukin

Animal cell line...

293-EBNA; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interl

Animal cell line...

70Z/3; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleuk

Animal cell line...

9T7; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin

CAS REGISTRY NUMBERS:

404323-42-8 404323-43-9 amino acid sequence; sequence characterization and function of

11028-71-0 isolated nucleic acid mols. which encode T cell inducible factors (TIFs), proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin-9 effects

404326-59-6 404326-60-9 404326-61-0 404326-62-1 404326-63-2

404326-64-3 404326-65-4 404326-66-5 404326-67-6 404326-68-7

404326-69-8 404326-70-1 404326-71-2 404326-72-3 404326-73-4

404326-74-5 404326-75-6 404326-76-7 404326-77-8 404326-78-9

404326-79-0 404326-80-3 404326-81-4 404326-82-5 404326-83-6

unclaimed nucleotide sequence; isolated nucleic acid mols. which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof in prepn. of antibodies and immunogens and in study of STAT activation and interleukin-9 effects

3/7/13 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136166068 CA: 136(11)166068e PATENT

Human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

INVENTOR(AUTHOR): Dumoutier, Laure; Renauld, Jean-Christophe

LOCATION: USA

ASSIGNEE: Ludwig Institute for Cancer Research

PATENT: PCT International ; WO 200210393 A2 DATE: 20020207

APPLICATION: WO 2001US20485 (20010627) \*US 626617 (20000727)

PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/24A; C12N-015/63B; C07K-014/54B; G01N-033/50B DESIGNATED COUNTRIES: AU; BR; CA; CN; JP DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE ; IT; LU; MC; NL; PT; SE; TR

SECTION:

CA215005 Immunochemistry

IDENTIFIERS: sequence interleukin 21 gene human, transcription factor STAT induction IL21 human mouse, activation transcription interleukin 21 human

DESCRIPTORS:

Transcriptional regulation...

activation; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Proteins...

acute-phase, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Gene, animal...

encoding IL-21; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Thymus gland... Brain...

expression of IL-21 in mouse; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

B cell(lymphocyte)...  
 expression of IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

T cell(lymphocyte)...  
 helper cell, IL-9 upregulated IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Liver...  
 hepatocyte; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Liver,neoplasm...  
 hepatoma, induction of STAT in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Human... cDNA sequences... DNA sequences... Genetic mapping... Mammalia...

Drug screening... Mouse...  
 human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Chromosome...  
 human 12, q15; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Mast cell...  
 IL-9 upregulated IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Lipopolysaccharides...  
 induction of IL-21 with; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Haptoglobin...  
 induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Kidney...  
 mesangium, melanoam, induction of STAT in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Nerve...  
 neuron, melanoam, induction of STAT in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Antibodies...  
 of IL-10R.beta.; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Interleukin 10...  
 R.beta.; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Proteins...  
 SAA (serum amyloid A), induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Transcription factors...  
 STAT, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Transcription factors...  
 STAT1, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Transcription factors...  
 STAT3, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Transcription factors...  
 STAT5, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Interleukin 4...  
 upregulation of IL-21 in TS1 cell with; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Interleukin 9...  
 upregulation of IL-21 with; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies

Interleukins...  
 21.alpha.; human T cell inducible factors, interleukin-21, sequences,

chromosomal mapping, and function studies  
 Interleukins...  
 21.beta.; human T cell inducible factors, interleukin-21, sequences,  
 chromosomal mapping, and function studies  
 Interleukins...  
 21; human T cell inducible factors, interleukin-21, sequences,  
 chromosomal mapping, and function studies  
 CAS REGISTRY NUMBERS:  
 9004-07-3 .alpha.1-chymotrypsin, induction of; human T cell inducible  
 factors, interleukin-21, sequences, chromosomal mapping, and function  
 studies  
 394754-56-4 394754-57-5 nucleotide sequence; human T cell inducible  
 factors, interleukin-21, sequences, chromosomal mapping, and function  
 studies  
 394754-66-6 394754-67-7 394754-68-8 394754-69-9 394754-70-2  
 394754-71-3 394754-72-4 394754-73-5 394754-74-6 394754-75-7  
 394754-76-8 394754-77-9 394754-78-0 394754-79-1 394754-80-4  
 394754-81-5 394754-82-6 394754-83-7 394754-84-8 394754-85-9  
 394754-86-0 394754-87-1 394754-88-2 394754-89-3 394754-90-6  
 394754-91-7 394754-92-8 394754-93-9 394754-94-0 394754-95-1  
 394754-96-2 394754-97-3 394754-98-4 394754-99-5 394755-02-3  
 unclaimed nucleotide sequence; human T cell inducible factors,  
 interleukin-21, sequences, chromosomal mapping, and function studies  
 394755-00-1 394755-01-2 394755-03-4 unclaimed protein sequence; human T  
 cell inducible factors, interleukin-21, sequences, chromosomal mapping,  
 and function studies  
 11028-71-0 upregulation of IL-2 with; human T cell inducible factors,  
 interleukin-21, sequences, chromosomal mapping, and function studies  
 ? ds

Set	Items	Description
S1	89	E5-E12
S2	25	S1 AND (T(W)CELL(W)INDUCIBLE OR TIF?)
S3	13	RD S2 (unique items)

? s (t(w)cell(w)inducible or tif?)

Processing

4539746	T
7114250	CELL
135929	INDUCIBLE
27	T(W)CELL(W)INDUCIBLE
7356	TIF?
S4	7377 (T(W)CELL(W)INDUCIBLE OR TIF?)

? s (t(w)cell(w)inducible(w)Factor?)

Processing

4539746	T
7114250	CELL
135929	INDUCIBLE
4632057	FACTOR?
S5	7 (T(W)CELL(W)INDUCIBLE(W)FACTOR?)

? rd s5

...completed examining records

S6	5	RD S5 (unique items)
----	---	----------------------

? t s6/3/all

6/3/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2003 BIOSIS. All rts. reserv.

13611722 BIOSIS NO.: 200200240543  
 Isolated nucleic acid molecules which encode **T cell**  
**inducible factors** (TIFs), the proteins encoded, and uses  
 therefor.  
 AUTHOR: Dumoutier Laure(a); Louhed Jamila; Renauld Jean-Christophe  
 AUTHOR ADDRESS: (a)Brussels\*\*Belgium

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1256 (3):pNo Pagination Mar. 19, 2002  
MEDIUM: e-file  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

13505673 BIOSIS NO.: 200200134494  
Isolated nucleic acid molecules which encode T cell  
inducible factors (TIFS), the proteins encoded, and uses  
thereof.  
AUTHOR: Dumoutier Laure(a); Louhed Jamila; Renauld Jean-Christophe  
AUTHOR ADDRESS: (a)Brussels\*\*Belgium  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1253 (3):pNo Pagination Dec. 18, 2001  
MEDIUM: e-file  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136246402 CA: 136(16)246402z PATENT  
Isolated nucleic acid molecules which encode T cell inducible factors  
(TIFs), the proteins encoded, and uses thereof in prepn. of antibodies and  
immunogens and in study of STAT activation and interleukin-9 effects  
INVENTOR(AUTHOR): Dumoutier, Laure; Louhed, Jamila; Renauld,  
Jean-Christophe  
LOCATION: USA  
ASSIGNEE: Ludwig Institute for Cancer Research  
PATENT: United States ; US 6359117 B1 DATE: 20020319  
APPLICATION: US 354243 (19990716) \*US 178973 (19981026)  
PAGES: 23 pp., Cont.-in-part of U.S. Ser. No. 178,973. CODEN: USXXAM  
LANGUAGE: English CLASS: 530351000; C07K-014/52A

6/3/4 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136182472 CA: 136(12)182472n PATENT  
Soluble zcytor 11 cytokine receptors  
INVENTOR(AUTHOR): Kindsvogel, Wayne R.; Topouzis, Stavros  
LOCATION: USA  
ASSIGNEE: Zymogenetics, Inc.  
PATENT: PCT International ; WO 200212345 A2 DATE: 20020214  
APPLICATION: WO 2001US24838 (20010808) \*US PV223827 (20000808) \*US  
PV250876 (20001201)  
PAGES: 117 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/705A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;  
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;

MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ  
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;  
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/5 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

136166068 CA: 136(11)166068e PATENT  
Human T cell inducible factors, interleukin-21, sequences, chromosomal  
mapping, and function studies  
INVENTOR(AUTHOR): Dumoutier, Laure; Renauld, Jean-Christophe  
LOCATION: USA  
ASSIGNEE: Ludwig Institute for Cancer Research  
PATENT: PCT International ; WO 200210393 A2 DATE: 20020207  
APPLICATION: WO 2001US20485 (20010627) \*US 626617 (20000727)  
PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/24A;  
C12N-015/63B; C07K-014/54B; G01N-033/50B DESIGNATED COUNTRIES: AU; BR; CA;  
CN; JP DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE  
; IT; LU; MC; NL; PT; SE; TR  
? s IL(w)21

343485 IL  
988955 21  
S7 132 IL(W)21  
? rd s7  
...examined 50 records (50)  
...examined 50 records (100)  
...completed examining records  
S8 73 RD S7 (unique items)  
? s s8 and py<2000  
Processing  
Processing  
73 S8  
46481470 PY<2000  
S9 13 S8 AND PY<2000  
? rd s9  
...completed examining records  
S10 13 RD S9 (unique items)  
? t s10/3/all

10/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

11478406 BIOSIS NO.: 199800259738  
The observation on treatment effects of local adoptive immunotherapy in 33  
cases with head and neck cancer.  
AUTHOR: Han Demin; Zhu Xiaonong; Huang Zhigang; et al  
AUTHOR ADDRESS: Beijing Inst. Otolaryngol., Beijing 100005\*\*China  
JOURNAL: Zhonghua Zhongliu Zazhi 19 (6):p454-456 Nov., 1997  
ISSN: 0253-3758  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Chinese; Non-English  
SUMMARY LANGUAGE: Chinese; English

10/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

10148722 BIOSIS NO.: 199698603640  
Spontaneous and glucocorticoid-induced apoptosis in human mature T

lymphocytes.  
AUTHOR: Burnetti Mauro(a); Martelli Nicola; Colasante Antonella; Piantelli  
Mauro; Musiani Piero; Aiello Francesca B  
AUTHOR ADDRESS: (a)Lab. Immunopathol., Consorzio Mario Negri Sud, 66030  
Santa Maria Imbaro\*\*Italy  
JOURNAL: Blood 86 (11):p4199-4205 1995  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

10062218 BIOSIS NO.: 199598517136  
T-cell suppression and selective in vivo activation of TH2 subpopulation by  
the Entamoeba histolytica 220-kilodalton lectin.  
AUTHOR: Talamas-Rohana Patricia(a); Schlie-Guzman Maria Adelina;  
Hernandez-Ramirez Veronica I; Rosales-Encina Jose Luis  
AUTHOR ADDRESS: (a)Dep. Patologia Experimental, Centro Investigacion  
Estudios Avanzados IPN, Apdo. Postal 14-740, M\*\*Mexico  
JOURNAL: Infection and Immunity 63 (10):p3953-3958 1995  
ISSN: 0019-9567  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

08740460 BIOSIS NO.: 199395029811  
Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity  
of murine splenocyte cultures: Role of prostaglandin E-2 and interferons.  
AUTHOR: Vaillier Dominique(a); Daculsi Richard; Gualde Norbert  
AUTHOR ADDRESS: (a)URA 1456 CNRS, Univ. de Bordeaux, 146 rue Leo-Saignat,  
33076 Bordeaux Cedex\*\*France  
JOURNAL: Cancer Immunology Immunotherapy 35 (6):p395-400 1992  
ISSN: 0340-7004  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

08355994 BIOSIS NO.: 000094096517  
RENAL TUBULAR EPITHELIAL ANTIGEN-CONTAINING IMMUNE COMPLEXES STIMULATE  
INTERLEUKIN-1 PRODUCTION BY MONOCYTES FROM PATIENTS WITH  
GLOMERULONEPHRITIS  
AUTHOR: MATSUMOTO K  
AUTHOR ADDRESS: SECOND DEP. INTERNAL MED., NIHON UNIV. SCH. MED., TOKYO,  
JPN.  
JOURNAL: INT UROL NEPHROL 24 (3). 1992. 319-326. 1992  
FULL JOURNAL NAME: International Urology and Nephrology  
CODEN: IURNA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH



10/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07845233 BIOSIS NO.: 000092115399  
INTRAVENOUS VITAMINS FOR VERY-LOW-BIRTH-WEIGHT INFANTS  
AUTHOR: GREENE H L; SMITH R; POLLACK P; MURRELL J; CAUDILL M; SWIFT L  
AUTHOR ADDRESS: VANDERBILT UNIV. MED. CENT., DEP. PEDIATRICS, DIV.  
NUTRITION, D-4130 MEDICAL CENT. NORTH, NASHVILLE, TENN. 37232-2576.  
JOURNAL: J AM COLL NUTR 10 (4). 1991. 281-288. 1991  
FULL JOURNAL NAME: Journal of the American College of Nutrition  
CODEN: JONUD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

10/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07751133 BIOSIS NO.: 000092064854  
DISSOCIATION BETWEEN EARLY AND LATE EVENTS IN T CELL ACTIVATION MEDIATED  
THROUGH CD28 SURFACE MOLECULE  
AUTHOR: NUNES J; BAGNASCO M; LOPEZ M; LIPCEY C; MAWAS C; OLIVE D  
AUTHOR ADDRESS: UNITE CANCEROL. ET THERAPEUTIQUE EXP., U.119, INSERM, 27  
BLVD. LEI ROURE, 13009 MARSEILLE, FRANCE.  
JOURNAL: MOL IMMUNOL 28 (4-5). 1991. 427-436. 1991  
FULL JOURNAL NAME: Molecular Immunology  
CODEN: MOIMD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

10/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07343136 BIOSIS NO.: 000090123038  
ELEVATION OF CYCLIC AMP LEVELS INDEPENDENTLY DOWN REGULATES IL-1 IL-2 AND  
IL-2 RECEPTOR CD25 SYNTHESIS  
AUTHOR: IWAZ J; KOUASSI E; LAFONT S; REVILLARD J P  
AUTHOR ADDRESS: LAB. IMMUNOL., INSERM U.80, CNRS UA 1177, UCBL, HOP. E.  
HERRIOT, 69437 LYON CEDEX 03, FRANCE.  
JOURNAL: INT J IMMUNOPHARMACOL 12 (6). 1990. 631-638. 1990  
FULL JOURNAL NAME: International Journal of Immunopharmacology  
CODEN: IJIMD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

10/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07236207 BIOSIS NO.: 000090016081  
NUCLEAR EVENTS AFTER ACTIVATION OF CD4-POSITIVE-8-POSITIVE THYMOCYTES  
AUTHOR: RIEGEL J S; RICHIE E R; ALLISON J P  
AUTHOR ADDRESS: DEP. MICROBIOL. IMMUNOL., UNIV. CALIFORNIA BERKELEY,  
BERKELEY, CALIF. 94720.  
JOURNAL: J IMMUNOL 144 (9). 1990. 3611-3618. 1990  
FULL JOURNAL NAME: Journal of Immunology  
CODEN: JOIMA  
RECORD TYPE: Abstract

LANGUAGE: ENGLISH

10/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

04596611 BIOSIS NO.: 000079009648  
MEAT PRODUCTION AND CARCASS INDICATORS OF INTENSIVELY FATTENED LAMBS OF  
SOME BREEDS RAISED IN SOUTH BULGARIA 2  
AUTHOR: IVANOV I S; DIMITROV I  
AUTHOR ADDRESS: INST. CATTLE SHEEP BREED., STARA ZAGORA, BULG.  
JOURNAL: ZHIVOTNOV'D NAUKI 21 (1). 1984. 35-41. 1984  
FULL JOURNAL NAME: Zhivotnov'Dni Nauki  
CODEN: ZHVNA  
RECORD TYPE: Abstract  
LANGUAGE: BULGARIAN

10/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

03524616 BIOSIS NO.: 000073027696  
EFFECTS OF NITRATE LEVEL ON NITROGEN METABOLISM IN WINGED BEAN  
PSOPHOCARPUS-TETRAGONOLOBUS AND SOYBEAN GLYCINE-MAX  
AUTHOR: HILDEBRAND D F; HARPER J E; HYMOWITZ T  
AUTHOR ADDRESS: DEP. AGRONOMY, UNIV. ILLINOIS, URBANA, ILL. 61801.  
JOURNAL: ANN BOT (LOND) 48 (3). 1981. 307-314. 1981  
FULL JOURNAL NAME: Annals of Botany (London)  
CODEN: ANBOA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

10/3/12 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

01181170 72026870 PMID: 5000317  
[Notes on the round table discussion of the clinical studies of penthrane  
held at Santa Vittoria d'Alba on 21 June 1970 by the Associazione  
Anestesisti Rianimatori Ospedalieri Piemontesi]  
Atti della tavola rotonda su aggiornamenti clinici sul pentrane svoltasi  
a Santa Vittoria d'Alba il 21 giugno 1970 a cura  
dell'Associazione Anestesisti Rianimatori Ospedalieri Piemontesi.  
Minerva anesthesiologica (ITALY) Jun-Jul 1971, 37 (6) p257-88,  
ISSN 0375-9393 Journal Code: 0375272  
Document type: Journal Article  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: Completed

10/3/13 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

00207354 67160619 PMID: 5229075  
[Report on the activity of the Study Center during the academic year  
1964-65 compiled on Oct. 21, 1965]  
Relazione sull'attivit  del Centro Studi durante l'anno accademico  
1964-65 esposta il 21-10-1965.  
Palazzi S

Rassegna trimestrale di odontoiatria (ITALY) Jul-Sep 1966, 47  
(3) p259-76, ISSN 0033-9911 Journal Code: 20020625R  
Document type: Journal Article  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: Completed  
? t s10/7/all

10/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

11478406 BIOSIS NO.: 199800259738  
The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer.  
AUTHOR: Han Demin; Zhu Xiaonong; Huang Zhigang; et al  
AUTHOR ADDRESS: Beijing Inst. Otolaryngol., Beijing 100005\*\*China  
JOURNAL: Zhonghua Zhongliu Zazhi 19 (6):p454-456 Nov., 1997  
ISSN: 0253-3758  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Chinese; Non-English  
SUMMARY LANGUAGE: Chinese; English

ABSTRACT: Objective: To evaluate treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer. Methods: IL-21 X 10<sup>5</sup> apprx 2 X 10<sup>8</sup> per day was injected into tumor for 10 days; during the 4th-8th day LAK cells 1.0 X 10<sup>8</sup>-5.0 X 10<sup>8</sup> per day were combined with IL-2 injection. Then we analysed clinical effect, immunopathology, side effects, etc. Results: CR was seen in 1 case; PR in 6, MR in 20 cases, and SD in 6 cases. The one-, two-and three-year survival rate was 96.3%, 83.3% or 75.0% respectively. The results of histopathology showed that there were large amount of T lymphocytes (CD3+/4+) infiltrating in the tumor area after immunotherapy. No serious side effects were found during the course of the treatment. Conclusion: Local injection of IL-2/LAK can be used as immunotherapy for head and neck cancer.

10/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

10148722 BIOSIS NO.: 199698603640  
Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes.  
AUTHOR: Burnett Mauro(a); Martelli Nicola; Colasante Antonella; Piantelli Mauro; Musiani Piero; Aiello Francesca B  
AUTHOR ADDRESS: (a)Lab. Immunopathol., Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro\*\*Italy  
JOURNAL: Blood 86 (11):p4199-4205 1995  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Glucocorticoid (GC)-induced apoptosis is a well-recognized physiologic regulator of murine T-cell number and function. We have analyzed its mechanisms in human mature T cells, which have been thought to be insensitive until recently. Peripheral blood T cells showed sensitivity to GC-induced apoptosis soon after the proliferative response to a mitogenic stimulation, and were also sensitive to spontaneous (ie, growth factor deprivation-dependent) apoptosis. CD8+ T cells were more sensitive to both forms than CD4+ T cells. Acquisition of sensitivity to

GC-induced apoptosis was not associated with any change in number or affinity of GC receptors. Both spontaneous and GC-induced apoptosis were increased by the macromolecular synthesis inhibitors, cycloheximide (CHX) and puromycin. A positive correlation between the degree of protein synthesis inhibition and the extent of apoptosis was observed.. Interleukin-2 (IL-2), IL-4, and IL-10 protected (IL-2 gt IL-10 gt IL-4) T cells from both forms of apoptosis in a dose-dependent manner. Our data suggest that spontaneous and GC-induced apoptosis regulate the human mature T-cell repertoire by acting early after the immune response and differentially affecting T-cell subsets.

10/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

10062218 BIOSIS NO.: 199598517136  
T-cell suppression and selective in vivo activation of TH2 subpopulation by the *Entamoeba histolytica* 220-kilodalton lectin.  
AUTHOR: Talamas-Rohana Patricia(a); Schlie-Guzman Maria Adelina; Hernandez-Ramirez Veronica I; Rosales-Encina Jose Luis  
AUTHOR ADDRESS: (a)Dep. Patologia Experimental, Centro Investigacion Estudios Avanzados IPN, Apdo. Postal 14-740, M\*\*Mexico  
JOURNAL: Infection and Immunity 63 (10):p3953-3958 1995  
ISSN: 0019-9567  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: A 220-kDa surface protein (L220) with lectin activity from *Entamoeba histolytica* trophozoites has been characterized previously (J. L. Rosales-Encina, I. Meza, A. Lopez-de-Leon, P. Talamas-Rohana, and M. Rojkind, J. Infect. Dis. 156:790-797, 1987). This molecule is involved in the adhesion process (I. Meza, F. Cazares, J. L. Rosales-Encina, P. Talamas-Rohana, and M. Rojkind, J. Infect. Dis. 156:798-805, 1987) and is very immunogenic. In this work, we studied both the humoral and the cellular immune responses to L220. We compared L220 with L220-derived components, such as a fusion peptide (M-11) and chemically obtained peptides (by treating the 220-kDa molecule with N-chlorosuccinimide-urea). Spleen cells from L220-immunized mice were unable to proliferate in vitro when stimulated with the protein. However, a proliferative response was obtained when mice were immunized with the L220-derived fusion peptide or the cleaved lectin. To find out if there was a correlation between the observed responses and TH1 or TH2 activation, we analyzed patterns of cytokine secretion (interleukin-2 (IL-2), IL-4, IL-10, and gamma interferon). Cells from mice immunized with peptides that induced cell proliferation (100, 80, and 47 kDa) with the peptides (P lt 0.01) and with the intact molecule secreted IL-2 and gamma interferon, showing a TH1-subset pattern. Conversely, cells from mice immunized with the intact 220-kDa molecule secreted IL-4 and IL-10, typical of a TH2 subpopulation; however, antibodies from each group recognized the 220-kDa molecule as determined by Western blotting (immunoblotting). These results suggest that various epitopes in the 220-kDa molecule generate different response patterns, suppressing or activating T-cell responses.

10/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

08740460 BIOSIS NO.: 199395029811  
Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: Role of prostaglandin E-2 and interferons.

AUTHOR: Vaillier Dominique(a); Daculsi Richard; Gualde Norbert  
AUTHOR ADDRESS: (a)URA 1456 CNRS, Univ. de Bordeaux, 146 rue Leo-Saignat,  
33076 Bordeaux Cedex\*\*France  
JOURNAL: Cancer Immunology Immunotherapy 35 (6):p395-400 1992  
ISSN: 0340-7004  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Splenocytes cultured for 24 h in the presence of interleukin-2 (IL-2), lipopolysaccharide (LPS) or both together expressed a cytotoxic activity against the YAC-1 lymphoma cell line and to a lesser extent against P815 mastocytoma cells. The association of IL-2 and LPS had an additive effect on induction of cytotoxicity. The IL-2-induced cytotoxic activity lasted for the whole of the culture; however, the addition of LPS at the initiation of the culture increased the cytotoxic activity during its early phase, the increment being followed by a fall of lytic activity after 72 h of culture. Assessment of interferon (IFN) in the culture supernatant showed (a) a production of IFN-gamma by IL-2-supplemented cultures, (b) a more potent IFN production by cultures treated with IL-3 plus LPS (including 20% IFN-alpha/beta), (c) and that indomethacin (1-mu-M) potentiated the effect of either IL-2 or LPS used alone but did not significantly increase the cytotoxic activity of cultures treated with IL-21 plus LPS (the one that produced a high level of IFN). When cultures were treated by an anti-IFN antibody we observed no change in the cytotoxic activity; however, in the presence of anti-IFN-alpha/beta serum the cytotoxic activity of cultures treated with IL-2 plus LPS was inhibited after 24 h but stimulated after 72 h. When cultures treated with IL-2 plus LPS were supplemented with both indomethacin and anti-IFN-alpha/beta the cytotoxic activity assessed after 72 h of culture was maintained at the same level as that of IL-2-treated cultures, hence the fall after 72 h of the cytotoxicity of culture initiated in the presence of LPS alone was affected by both the immune serum and the cyclooxygenase inhibitor. Altogether these data show that when splenocytes are cultured for more than 72 h in the presence of IL-2 and LPS their cytotoxic activity decreases, and it is likely that this diminution is linked to the endogenous production of prostaglandin E-2 and IFN-alpha/beta.

10/7/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

08355994 BIOSIS NO.: 000094096517  
RENAL TUBULAR EPITHELIAL ANTIGEN-CONTAINING IMMUNE COMPLEXES STIMULATE  
INTERLEUKIN-1 PRODUCTION BY MONOCYTES FROM PATIENTS WITH  
GLOMERULONEPHRITIS  
AUTHOR: MATSUMOTO K  
AUTHOR ADDRESS: SECOND DEP. INTERNAL MED., NIHON UNIV. SCH. MED., TOKYO,  
JPN.  
JOURNAL: INT UROL NEPHROL 24 (3). 1992. 319-326. 1992  
FULL JOURNAL NAME: International Urology and Nephrology  
CODEN: IURNA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: We have investigated the effect of immune complexes (IC) derived from human renal tubular epithelial (RTE) antigen on the release of interleukin-1 (IL-1) in monocyte cultures from patients with glomerulonephritis (GN). When peripheral blood monocytes (PBM) were activated by IC, substantial amounts of IL-1 could be detected in the supernatants as measured by mouse thymocyte assay. The IC-induced IL-1 activity was significantly higher in patients with GN than in normal

controls. To avoid the effect of prostaglandins on the IL-1 assay, we cultured PBM with addition of indomethacin and assayed IL-1 activity in the culture supernatants. This cyclooxygenase inhibitor augmented IC-induced IL-21 production. The results suggest that IC are involved in stimulating IL-1 production by PBM and thus play a role in the immune response in GN.

10/7/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07845233 BIOSIS NO.: 000092115399

INTRAVENOUS VITAMINS FOR VERY-LOW-BIRTH-WEIGHT INFANTS

AUTHOR: GREENE H L; SMITH R; POLLACK P; MURRELL J; CAUDILL M; SWIFT L

AUTHOR ADDRESS: VANDERBILT UNIV. MED. CENT., DEP. PEDIATRICS, DIV.

NUTRITION, D-4130 MEDICAL CENT. NORTH, NASHVILLE, TENN. 37232-2576.

JOURNAL: J AM COLL NUTR 10 (4). 1991. 281-288. 1991

FULL JOURNAL NAME: Journal of the American College of Nutrition

CODEN: JONUD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Term infants and children appear to adapt to large variations in vitamin intakes. This is supported by the finding of similar blood levels of vitamins despite several-fold differences in intake on a body weight basis. By contrast, the finding of marked elevation of some vitamins and low levels of others seen in very-low-weight (VLBW) infants (< 1500 g) suggest that this group has less adaptive capacity to high- or low-dose intake. This indicates that their vitamin intakes need to be more closely aligned with actual needs. This paper reviews previously published data on vitamins A, E, B2, and B6 from VLBW infants receiving total parenteral nutrition (TPN). Vitamin A. VLBW infants are relatively deficient in retinol (R) at birth. During TPN large losses of R onto the delivery sets results in a further decline in stores of R as reflected in a progressive decline in plasma R during TPN. Because of the reported lower incidence of bronchopulmonary dysplasia associated with intramuscular vitamin A treatment, alternative methods of vitamin A delivery during TPN have been suggested. First, the vitamins were mixed with Intralipid (IL) and, second, retinyl palmitate (RP) rather than R was used. There was little in vitro loss of R when mixed with IL, and in vivo treatment resulted in higher blood levels after 1 month of retinol administration of IL than seen previously (21.4  $\pm$  4.2 vs 14.1  $\pm$  3.7  $\mu$ g/dl). Use of RP in VLBW infants resulted in high RP levels (40  $\pm$  6  $\mu$ g/dl), although R levels were similar to that seen with R added to IL (21.1  $\pm$  4  $\mu$ g/dl). Using these data and those from other publications, currently suggested intravenous intake of vitamin A as R is 500  $\mu$ g/kg/day. Vitamin E. The TPN solution for pediatric patients contains  $\alpha$ -tocopherol acetate. Little of the vitamin is lost to the plastic infusion sets. Infusion of four different dosage levels suggests that doses of 2.8-3.5 mg/kg/day will maintain most infant blood levels between 1 and 2 mg/dl. Vitamin B2. Vitamin B2 is activated to its active cofactor forms flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). Three doses of riboflavin (0.68, 0.56, and 0.34 mg/kg/day) resulted in elevated blood levels. Using these blood response doses, a projected intake of 0.15 mg/kg/day appears more appropriate to maintain blood levels in the range of those seen in formula-fed term infants. Vitamin B6. Vitamin B6 is converted in vivo to pyridoxal and activated to its cofactor form, pyridoxal phosphate (PLP). Three doses of pyridoxine (from 0.2 to 0.5 mg/kg/day) resulted in elevated blood levels. Using the blood response to these doses, an intake of 0.18 mg/kg/day is projected to maintain PLP levels within the range of that seen in plasma samples from formula-fed term infants.

10/7/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07751133 BIOSIS NO.: 000092064854  
DISSOCIATION BETWEEN EARLY AND LATE EVENTS IN T CELL ACTIVATION MEDIATED  
THROUGH CD28 SURFACE MOLECULE  
AUTHOR: NUNES J; BAGNASCO M; LOPEZ M; LIPCEY C; MAWAS C; OLIVE D  
AUTHOR ADDRESS: UNITE CANCEROL. ET THERAPEUTIQUE EXP., U.119, INSERM, 27  
BLVD. LEI ROURE, 13009 MARSEILLE, FRANCE.  
JOURNAL: MOL IMMUNOL 28 (4-5). 1991. 427-436. 1991  
FULL JOURNAL NAME: Molecular Immunology  
CODEN: MOIMD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: The regulation of early and late events of T cell activation via the CD28 molecule has been investigated, using as an indicator system the differentiated leukemic T cell line Jurkat. Both CD3 and CD28 mAbs induced an increase in  $(Ca^{2+})_i$  in Jurkat cells, although with different kinetics, the latter being slower than the former. CD28-mediated  $(Ca^{2+})_i$  mobilization was highly sensitive to cholera toxin (ID<sub>50</sub> 25 ng/ml, vs 300 ng/ml for CD3 stimulation). The inhibitory action of cholera toxin was neither merely due to the increase in intracellular cAMP concentrations, nor to decrease in cell surface expression of the CD28 molecule. To evaluate the effects of cholera toxin on late events of Jurkat cell activation induced by CD28 and CD3 mAbs, the action of cholera toxin and cAMP and CD3- and CD28-mediated IL-2 secretion was analyzed. CD3-induced IL-2 secretion was highly sensitive to cholera toxin (ID < 5 ng/ml); on the other hand, CD28-induced IL-2 secretion was poorly sensitive to cholera toxin, in sharp contrast to  $(Ca^{2+})_i$  mobilization. On the basis of these data, it is hypothesized that the CD28 pathway could be associated with at least two distinct transduction mechanisms, one responsible for the  $(Ca^{2+})_i$  rise in Jurkat cells and highly sensitive to cholera toxin, and the other, whose second messenger is unknown, resistant to cholera toxin and responsible for IL-2 secretion.

10/7/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07343136 BIOSIS NO.: 000090123038  
ELEVATION OF CYCLIC AMP LEVELS INDEPENDENTLY DOWN REGULATES IL-1 IL-2 AND  
IL-2 RECEPTOR CD25 SYNTHESIS  
AUTHOR: IWAZ J; KOUASSI E; LAFONT S; REVILLARD J P  
AUTHOR ADDRESS: LAB. IMMUNOL., INSERM U.80, CNRS UA 1177, UCBL, HOP. E.  
HERRIOT, 69437 LYON CEDEX 03, FRANCE.  
JOURNAL: INT J IMMUNOPHARMACOL 12 (6). 1990. 631-638. 1990  
FULL JOURNAL NAME: International Journal of Immunopharmacology  
CODEN: IJIMD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: In view of the central involvement of interleukin-1 (IL-1) in T-cell functions and the negative effects exerted by cyclic adenosine monophosphate (cAMP) on T-cell responses, we wondered whether these inhibitions rely on defects in IL-1 generation. We investigated the effect of a known cAMP elevating agent, cholera toxin (CT), on the generation of IL-1 from peripheral blood adherent cells as well as the role of IL-1 whenever IL-2 synthesis and IL-2 receptor (CD25 antigen) expression are inhibited. While augmenting intracellular cAMP concentration, CT inhibits from 20 to 40% the generation of IL-1 activity

from Escherichia coli lipopolysaccharide (LPS)-stimulated adherent cells. Theophylline (TH), a cAMP degradation blocking agent, induces the same decrease in IL-1 activity. The B chain of CT, devoid of cAMP activating potency, is not inhibitory. In systems where CT and TH dramatically inhibit the generation of IL-2 activity (80%), addition of exogenous IL-1 does not restore the ability of T-cells to produce or release IL-2. Moreover, CT- and dibutyryl (db)cAMP-induced inhibition of CD25 antigen expression is not overcome by exogenous IL-1, IL-21, nor by both interleukin. It is concluded that inhibition of IL-1 and IL-2 production are independent and that inhibition of CD25 antigen expression is independent of IL-1 and IL-2 modulation. Cholera toxin and cAMP influences on interleukin synthesis are discussed.

10/7/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07236207 BIOSIS NO.: 000090016081  
NUCLEAR EVENTS AFTER ACTIVATION OF CD4-POSITIVE-8-POSITIVE THYMOCYTES  
AUTHOR: RIEGEL J S; RICHIE E R; ALLISON J P  
AUTHOR ADDRESS: DEP. MICROBIOL. IMMUNOL., UNIV. CALIFORNIA BERKELEY,  
BERKELEY, CALIF. 94720.  
JOURNAL: J IMMUNOL 144 (9). 1990. 3611-3618. 1990  
FULL JOURNAL NAME: Journal of Immunology  
CODEN: JOIMA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: Functionally mature T cells respond to stimulation via the Ag receptor by secretion of IL-2 and/or other lymphokines and by proliferation. However, immature CD4+8+ thymocytes do not secrete IL-2 or proliferate in response to stimulation. We have analyzed murine thymocyte populations enriched for CD4+ and CD4+8+ cells as well as the functionally mature CD4+ lymphoma C6VL-B and the CD4+8+ lymphoma 1010 for their ability to express mRNA related to early products of T cell activation signals. When stimulated with the calcium ionophore (Ionomycin) plus PMA, all the cells, regardless of their phenotype, accumulated abundant levels of c-myc mRNA. However, in contrast to the CD4+ thymocytes and C6VL-B, which accumulated abundant levels of IL-21 transcripts, neither the normal CD4+8+ thymocytes nor 1010 expressed IL-2 mRNA before or after stimulation. We have also examined these cells for the presence of the murine equivalents of two nuclear DNA-binding factors, NFAT-1 and NFIL-2-A, which have been shown to be involved in IL-2 gene expression in human T cells. Our results indicate: 1) NFIL-2A binding activity is constitutively expressed in both CD4+ and CD4+8+ thymocytes and lymphomas and 2) NFAT-1 binding activity is readily detected in CD4+ thymocytes and C6VL-B, but is detected in very minimal amounts in populations enriched for CD4+8+ thymocytes and in 1010 upon activation. These results suggest that the failure of CD4+8+ thymocytes to express IL-2 mRNA upon stimulation may be in part due to the lack of inducibility of NFAT-1 binding activity, and that functional maturation of this population might be associated with acquisition of the ability to induce NFAT-1 activity.

10/7/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

04596611 BIOSIS NO.: 000079009648  
MEAT PRODUCTION AND CARCASS INDICATORS OF INTENSIVELY FATTENED LAMBS OF  
SOME BREEDS RAISED IN SOUTH BULGARIA 2  
AUTHOR: IVANOV I S; DIMITROV I



AUTHOR ADDRESS: INST. CATTLE SHEEP BREED., STARA ZAGORA, BULG.  
JOURNAL: ZHIVOTNOV'D NAUKI 21 (1). 1984. 35-41. 1984  
FULL JOURNAL NAME: Zhivotnov'Dni Nauki  
CODEN: ZHVNA  
RECORD TYPE: Abstract  
LANGUAGE: BULGARIAN

ABSTRACT: A scientific-economic experiment was carried out in 1980 at the Cattle and Sheep Breeding Research Institute in Stara Zagora with 90 lambs of the following breeds: Ile de France, semi-fine fleece, crossbred type lambs from Kazanluk region and Tsigai lambs from Topolovgrad region. There were 30 male lambs in each group, analogically equalized as regards age, type of lambing and live weight. Lambs were included in the experiment after reaching an age of 35-37 days and were fattened during a period of 80-105 days. At reaching live weights of 25, 30, 35 and 40 kg, 6 lambs from each group or a total of 24 lambs from each group were slaughtered in order to establish the quantitative and carcass indicators. Feed efficiency per kilogram of gain declines with age and increase in live weight, the rate of declining for Ile de France and Tsigai lambs being considerably higher reaching a live weight of 30 kg. The lambs of studied breeds reach the prescribed live weights at different ages. With the increase of live weight this difference between Ile de France lambs on the one side and semi-fine fleece and Tsigai type lambs on the other increases from 6-7 days to 11-21 days. Ile de France lambs are distinguished by highest carcass yield and percentage of meat in carcass at all 4 live weights. Tsigai type lambs accumulate greatest quantity of meat at 25-30 kg live weight and semi-fine fleece lambs at 35-40 kg live weight. As live weight increases, the percentage content of protein in the absolute dry matter decreases from 86.34% to 67.35% but the percent content of fat increases and reaches maximum values at 35-40 kg live weight.

10/7/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

03524616 BIOSIS NO.: 000073027696  
EFFECTS OF NITRATE LEVEL ON NITROGEN METABOLISM IN WINGED BEAN  
PSOPHOCARPUS-TETRAGONOLOBUS AND SOYBEAN GLYCINE-MAX  
AUTHOR: HILDEBRAND D F; HARPER J E; HYMOWITZ T  
AUTHOR ADDRESS: DEP. AGRONOMY, UNIV. ILLINOIS, URBANA, ILL. 61801.  
JOURNAL: ANN BOT (LOND) 48 (3). 1981. 307-314. 1981  
FULL JOURNAL NAME: Annals of Botany (London)  
CODEN: ANBOA  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

ABSTRACT: The effects of high (15 mM) and low (0.75 mM) solution nitrate levels on N metabolism in 3 genotypes (IL 7A, IL 13 and IL 21) of winged beans [P. tetragonolobus (L.) DC.] and 1 genotype (Williams) of soybean [G. max (L.) Merrill] were investigated. Plants were grown for 42 days in a greenhouse in solution culture prior to sampling. The 15 mM nitrate treatment resulted in greater growth of all plant parts except roots. Growth of soybeans was more responsive to nitrate level than was growth of winged beans. The high nitrate level inhibited nodulation in all plants. The IL 13 and IL 21 winged bean genotypes had similar nitrogenase activity (acetylene reduction per plant) as the soybean and IL 7A winged bean genotype had lower activity. The IL 13 winged bean genotype had higher nitrogenase activity (acetylene reduction [N<sub>2</sub> fixation] per unit nodule mass) than the other 3 genotypes which all had similar activity. The 15 mM solution nitrate level stimulated leaf and root nitrate reductase (NR) activity for all plants. All winged bean genotypes had higher leaf NR activity and higher percentage reduced- and

nitrate-N contents of leaves and stems compared with soybeans. Total protein (reduced N) was greater in soybeans when sampled indicating that more nitrate had been metabolized by soybeans than by winged beans during the 42-day growth period.

10/7/12 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

01181170 72026870 PMID: 5000317  
[Notes on the round table discussion of the clinical studies of penthrane held at Santa Vittoria d'Alba on 21 June 1970 by the Associazione Anestesisti Rianimatori Ospedalieri Piemontesi]  
Atti della tavola rotonda su aggiornamenti clinici sul penthrane svoltasi a Santa Vittoria d'Alba il 21 giugno 1970 a cura dell'Associazione Anestesisti Rianimatori Ospedalieri Piemontesi.  
Minerva anesthesiologica (ITALY) Jun-Jul 1971, 37 (6) p257-88,  
ISSN 0375-9393 Journal Code: 0375272  
Document type: Journal Article  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: Completed  
Record Date Created: 19720104  
Record Date Completed: 19720104

10/7/13 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

00207354 67160619 PMID: 5229075  
[Report on the activity of the Study Center during the academic year 1964-65 compiled on Oct. 21, 1965]  
Relazione sull'attivita del Centro Studi durante l'anno accademico 1964-65 esposta il 21-10-1965.  
Palazzi S  
Rassegna trimestrale di odontoiatria (ITALY) Jul-Sep 1966, 47  
(3) p259-76, ISSN 0033-9911 Journal Code: 20020625R  
Document type: Journal Article  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: Completed  
Record Date Created: 19670720  
Record Date Completed: 19670720  
? s interleukin(w)21  
505552 INTERLEUKIN  
988955 21  
S11 141 INTERLEUKIN(W)21  
? rd s11  
...examined 50 records (50)  
...examined 50 records (100)  
...completed examining records  
S12 75 RD S11 (unique items)  
? s interleukin(w)21(20n) (nucleic or dna)  
505552 INTERLEUKIN  
988955 21  
659886 NUCLEIC  
2312539 DNA  
S13 10 INTERLEUKIN(W)21(20N) (NUCLEIC OR DNA)  
? rd s13  
...completed examining records  
S14 10 RD S13 (unique items)  
? t s14/7/all

14/7/1 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

15342527 22768159 PMID: 12885940

Cytokine requirements for the growth and development of mouse NK cells in vitro.

Toomey Jennifer A; Gays Frances; Foster Don; Brooks Colin G  
School of Cell and Molecular Biosciences, The Medical School, Newcastle, United Kingdom.

Journal of leukocyte biology (United States) Aug 2003, 74 (2)  
p233-42, ISSN 0741-5400 Journal Code: 8405628

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Natural killer (NK) cells arise from immature progenitors present in fetal tissues and adult bone marrow, but the factors responsible for driving the proliferation and differentiation of these progenitors are poorly understood. Mouse NK cells had previously been thought not to express interleukin (IL)-2Ralpha chains, but we show here that immature and mature mouse NK cells express IL-2Ralpha chain mRNA and that low levels of IL-2Ralpha chains can be detected on the surface of immature and mature NK cells provided they are cultured in the absence of IL-2. Despite their potential expression of high-affinity IL-2 receptors, immature NK cells only proliferate if IL-2 is present at extremely high concentrations. Surprisingly, IL-15 can also only support the growth of immature NK cells at high, presumably nonphysiological concentrations. Although NK cells express mRNA for the high-affinity IL-15Ralpha chain, they also express a variety of alternately spliced transcripts whose protein products could potentially disrupt signaling through IL-15 receptors. The requirement for high concentrations of IL-2 and IL-15 suggests that if these cytokines play any role in the proliferative expansion of NK cells in vivo, they act indirectly via other cells or in cooperation with other factors. In support of the latter possibility, we report that the recently described cytokine IL-21 can markedly enhance the proliferation of immature (and mature) NK cells in the presence of doses of IL-2 and IL-15 that by themselves have little growth-promoting activity.

Record Date Created: 20030729

Record Date Completed: 20030909

14/7/2 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

13966694 22233738 PMID: 12297282

Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli.

Asano Ryutaro; Kudo Toshio; Makabe Koki; Tsumoto Kouhei; Kumagai Izumi; et al

Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan.

FEBS letters (Netherlands) Sep 25 2002, 528 (1-3) p70-6, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Interleukin-21 (IL-21) has recently been identified as a novel 4-helix-bundle type I cytokine possessing a cytokine receptor gamma chain essential for the immune response. We report the preparation and functional

characterization of Escherichia coli-expressed recombinant human IL-21 (rIL-21). The rIL-21, expressed as insoluble inclusion bodies in E. coli, was solubilized and then refolded by using a modified dialysis method. The introduction of redox reagents during refolding led to a dramatic increase in the refolding efficiency. Circular dichroism spectrum analysis showed that the refolded rIL-21 had an alpha-helix as a secondary structure, which is a characteristic of type I cytokines. Flow cytometry confirmed previous reports that rIL-21 binds to CD3-activated T cells (T-LAK) and to cell lines Raji, HL60, and Jurkat. rIL-21 stimulated the proliferation of T-LAK but not peripheral blood mononuclear cells, and this effect seems to be identical to that of co-stimulation with anti-CD3 antibody. Growth inhibition assay indicated that enhancement of the cytotoxicity of T-LAK to the human bile duct carcinoma TFK-1 depended on the concentration of rIL-21. Thus, refolded rIL-21 had activity identical to that of authentic IL-21 and enhanced the anti-tumor activity of T-LAK. These conclusions suggest the potential use of the refolded cytokine in adoptive immunotherapy using T-LAK cells and in the discovery of other functions of the cytokine.

Record Date Created: 20020925

Record Date Completed: 20021104

14/7/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10043842 21981751 PMID: 11986233

Interleukin-21 is a growth and survival factor for human myeloma cells.

Brenne Anne-Tove; Baade Ro Torstein; Waage Anders; Sundan Anders; Borset Magne; Hjorth-Hansen Henrik

Department of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway.

Blood (United States) May 15 2002, 99 (10) p3756-62, ISSN 0006-4971  
Journal Code: 7603509

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Interleukin-21 (IL-21) is a recently cloned cytokine with homology to IL-2, IL-4, and IL-15. In this study we examined the effects of IL-21 on human myeloma cells. We found that IL-21 induced proliferation and inhibited apoptosis of the IL-6-dependent human myeloma cell lines ANBL-6, IH-1, and OH-2. The potency of IL-21 was close to that of IL-6 in the OH-2 cell line. Neutralizing antibodies to IL-6 or the IL-6 receptor transducer chain (gp130) did not affect IL-21-induced DNA synthesis, indicating that IL-21-induced proliferation was not mediated through these proteins. Tumor necrosis factor (TNF), another stimulator of myeloma cell growth, up-regulated the expression level of IL-21 receptor (IL-21R), and combinations of TNF and IL-21 gave synergistic effects on myeloma cell proliferation. Furthermore, 4 of 9 purified samples of primary myeloma cells showed a significant increase in DNA synthesis on stimulation of the cells by IL-21. By Western blot analysis, we demonstrated that the intracellular signaling pathways of IL-21 in myeloma cells involved phosphorylation of Jak1, Stat3, and Erk1/2 (p44/42 mitogen-activated protein kinase). IL-21 is a novel growth and survival factor in multiple myeloma and may represent a target for future therapy.

Record Date Created: 20020502

Record Date Completed: 20020610

14/7/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09865354 21679750 PMID: 11821949

The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.

Ueda Chiyoko; Akasaka Takashi; Kurata Masayuki; Maesako Yoshitomo; Nishikori Momoko; Ichinohasama Ryo; Imada Kazunori; Uchiyama Takashi; Ohno Hitoshi

First Division, Department of Internal Medicine, Faculty of Medicine, Kyoto University, 54 Shogoin-Kawaramachi, Sakyo-ku, Kyoto 606-8507, Japan.

Oncogene (England) Jan 17 2002, 21 (3) p368-76, ISSN 0950-9232

Journal Code: 8711562

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

BCL6 translocation affecting the chromosomal band 3q27 can involve a number of non-immunoglobulin (non-IG) gene loci as partners. We report here that the gene for interleukin-21 receptor (IL-21R) is the partner of BCL6 in t(3;16)(q27;p11) translocation. The two breakpoints on 16p11 of a lymphoma cell line YM and case no. 1012 with diffuse large B-cell lymphoma, both of which carried t(3;16), were localized within the 27-kb intron 1 of IL-21R. As a result of t(3;16), the promoter region of IL-21R was substituted for the regulatory sequences of BCL6 in the same transcriptional orientation. Reverse transcriptase-mediated polymerase chain reaction revealed chimeric mRNA consisting of two non-coding exons 1a/1b of IL-21R and coding exons of BCL6 in both lymphoma cells. Fluorescence in situ chromosomal hybridization of YM metaphase cells revealed fusion signals that contained both the BCL6 and IL-21R sequences on the der(3)t(3;16) chromosome. IL-21R was actively transcribed in YM cells, while BCL6 that was under the control of the IL-21R promoter was only moderately expressed at the mRNA and protein level. We constructed expression plasmid of BCL6 that followed the promoter sequences of IL-21R. COS-7 cells transiently transfected with the plasmid expressed high level Bcl-6 protein and displayed nuclear staining with a characteristic punctate pattern by immunofluorescence, indicating that expression of BCL6 can be enhanced by t(3;16). This study added to the list of non-IG partners of BCL6 translocations a new class of gene, i.e. cytokine receptor gene, the expression of which is closely associated with lymphoid cells.

Record Date Created: 20020131

Record Date Completed: 20020214

14/7/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

09531754 21311845 PMID: 11418623

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex.

Asao H; Okuyama C; Kumaki S; Ishii N; Tsuchiya S; Foster D; Sugamura K  
Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan. asao-h@mail.cc.tohoku.ac.jp

Journal of immunology (Baltimore, Md. - 1950) (United States) Jul 1 2001, 167 (1) p1-5, ISSN 0022-1767 Journal Code: 2985117R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

The common gamma-chain (gamma(c)) is an indispensable subunit of the functional receptor complexes for IL-4, IL-7, IL-9, and IL-15 as well as IL-2. Here we show that the gamma(c) is also shared with the IL-21R complex. Although IL-21 binds to the IL-21R expressed on gamma(c)-deficient ED40515(-) cells, IL-21 is unable to transduce any intracytoplasmic signals. However, in EDgamma-16 cells, a gamma(c)-transfected ED40515(-)

cell line, IL-21 binds to the IL-21R and can activate Janus kinase (JAK)1, JAK3, STAT1, and STAT3. The chemical cross-linking study reveals the direct binding of IL-21 to the gamma(c). These data clearly demonstrate that the gamma(c) is an indispensable subunit of the functional IL-21R complex.

Record Date Created: 20010621

Record Date Completed: 20010920

14/7/6 (Item 6 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2003 The Dialog Corp. All rts. reserv.

09402875 21169212 PMID: 11267886  
Cytokines: IL-21 joins the gamma(c)-dependent network?  
Vosshenrich C A; Di Santo J P  
Unite des Cytokines et Developpement Lymphoide, Institut Pasteur, 25 rue  
du Dr Roux, 75742, Paris, France. vosshenr@pasteur.fr  
Current biology - CB (England) Mar 6 2001, 11 (5) pR175-7, ISSN  
0960-9822 Journal Code: 9107782  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed  
The discovery of the cytokine IL-21 adds another member to the  
ever-growing list of small secreted molecules that have potent effects on  
lymphoid cells. Initial characterization of the IL-21 receptor complex  
suggests that IL-21 may belong to the cytokine family whose receptors share  
the common gamma chain, gamma(c).  
Record Date Created: 20010327  
Record Date Completed: 20010628

14/7/7 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

139035100 CA: 139(3)35100y PATENT  
Methods and compositions for modulating interleukin-21 (IL-21) or IL-21  
receptor (IL-21R) activity and therapeutic uses  
INVENTOR(AUTHOR): Carter, Laura; Carreno, Beatriz; Lowe, Leslie D.;  
Whitters, Matthew J.; Dunussi, Kyri; Collins, Mary; Ma, Margery; Young,  
Deborah A.; Witek, Joann S.; Larsen, Glenn; Kasaian, Marion T.; Donaldson,  
Debra D.; Unger, Michelle  
LOCATION: USA  
ASSIGNEE: Wyeth, John, and Brother Ltd.  
PATENT: U.S. Pat. Appl. Publ. ; US 20030108549 A1 DATE: 20030612  
APPLICATION: US 264634 (20021004) \*US 40005 (19980317) \*US 560766  
(20000428) \*US 569384 (20000511) \*US 972218 (20011004) \*US PV373746  
(20020417)  
PAGES: 109 pp., Cont.-in-part of U.S. Ser. No. 972,218. CODEN: USXXCO  
LANGUAGE: English CLASS: 424145100; A61K-039/395A; A61K-031/525B;  
A61K-031/4745B; A61K-031/415B  
SECTION:  
CA215005 Immunochemistry  
CA201XXX Pharmacology  
CA203XXX Biochemical Genetics  
CA263XXX Pharmaceuticals  
IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant  
immunostimulant, autoimmune disease cancer infection soluble IL21 receptor  
agonist antagonist  
DESCRIPTORS:  
Immunostimulants...  
adjuvants; interleukin-21 receptor agonists and antagonists for  
treating transplant rejection, autoimmune diseases, cancers and

infections  
 Interleukin 12... Interleukin 15... Interleukin 17... Interleukin 18...  
 Tumor necrosis factors...  
   agonists and antagonists; interleukin-21 receptor agonists and  
   antagonists for treating transplant rejection, autoimmune diseases,  
   cancers and infections  
 Spinal column,disease...  
   ankylosing spondylitis; interleukin-21 receptor agonists and  
   antagonists for treating transplant rejection, autoimmune diseases,  
   cancers and infections  
 Antibodies...  
   anti-IL-21R; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 CD22(antigen)... CD4(antigen)...  
   antibodies; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 Cytotoxic agents...  
   antimetabolites; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 Dermatitis...  
   atopic; interleukin-21 receptor agonists and antagonists for treating  
   transplant rejection, autoimmune diseases, cancers and infections  
 Thyroid gland,disease...  
   autoimmune thyroiditis; interleukin-21 receptor agonists and  
   antagonists for treating transplant rejection, autoimmune diseases,  
   cancers and infections  
 Estrogen receptors...  
   .beta. agonist; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 Drug delivery systems...  
   carriers; interleukin-21 receptor agonists and antagonists for treating  
   transplant rejection, autoimmune diseases, cancers and infections  
 Antibodies...  
   chimeric; interleukin-21 receptor agonists and antagonists for treating  
   transplant rejection, autoimmune diseases, cancers and infections  
 Intestine,disease...  
   Crohn's; interleukin-21 receptor agonists and antagonists for treating  
   transplant rejection, autoimmune diseases, cancers and infections  
 B cell(lymphocyte)...  
   depletion; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 Lymphocyte...  
   effector cell; interleukin-21 receptor agonists and antagonists for  
   treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 Protein motifs...  
   extracellular domain; interleukin-21 receptor agonists and antagonists  
   for treating transplant rejection, autoimmune diseases, cancers and  
   infections  
 cDNA sequences...  
   for IL-21 receptor from human and mouse; interleukin-21 receptor  
   agonists and antagonists for treating transplant rejection, autoimmune  
   diseases, cancers and infections  
 Immunoglobulins...  
   fragments, anti-IL-21R; interleukin-21 receptor agonists and  
   antagonists for treating transplant rejection, autoimmune diseases,  
   cancers and infections  
 Immunoglobulins...  
   fragments; interleukin-21 receptor agonists and antagonists for

treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
 G; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
 G1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
 G2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...  
 humanized; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Mouse...  
 IL-21R/MU-1 from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Disease, animal...  
 immune cell-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
 immunoconjugates; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Neoplasm...  
 immunotherapy; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
 immunotoxins; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Parasite...  
 infection by; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Intestine, disease...  
 inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Cytokines... Enzymes, biological studies...  
 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Diabetes mellitus...  
 insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Interleukin receptors...  
 interleukin-21, MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Allergy... Animal tissue culture... Antimicrobial agents... Antitumor agents... Anti-inflammatory agents... Arthritis... Asthma... Autoimmune disease... B cell (lymphocyte)... CD4-positive T cell... CD8-positive T cell... Cytotoxic agents... Dermatitis... DNA sequences... Drug delivery systems... Drugs... Eczema... Fusion proteins (chimeric proteins)... Genetic vectors... Growth inhibitors, animal... Human... Immunoglobulin receptors... Immunoglobulins... Immunostimulants... Immunosuppressants... Immunotherapy... Leukemia... Lymphocyte... Lymphoma... Macrophage... Megakaryocyte... Molecular cloning... Multiple sclerosis... Myasthenia gravis...



Osteoarthritis... Protein sequences... Psoriasis... Radionuclides...  
 Rheumatoid arthritis... T cell(lymphocyte)... Toxins... Transplant  
 rejection... Vaccines...  
     interleukin-21 receptor agonists and antagonists for treating  
     transplant rejection, autoimmune diseases, cancers and infections  
 Rheumatoid arthritis...  
     juvenile; interleukin-21 receptor agonists and antagonists for treating  
     transplant rejection, autoimmune diseases, cancers and infections  
 T cell(lymphocyte)...  
     memory; interleukin-21 receptor agonists and antagonists for treating  
     transplant rejection, autoimmune diseases, cancers and infections  
 Antibodies...  
     monoclonal; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Lymphocyte...  
     natural killer cell; interleukin-21 receptor agonists and antagonists  
     for treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Antibodies...  
     neutralizing; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Transcription factors...  
     NF-.kappa.B (nuclear factor of .kappa. light chain gene enhancer in  
     B-cells), inhibitors; interleukin-21 receptor agonists and antagonists  
     for treating transplant rejection, autoimmune diseases, cancer  
 Anti-inflammatory agents...  
     nonsteroidal; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Selectins...  
     P-, inhibitors; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Glycoproteins...  
     PSGL-1 (P-selectin glycoprotein ligand-1), inhibitors; interleukin-21  
     receptor agonists and antagonists for treating transplant rejection,  
     autoimmune diseases, cancers and infections  
 Arthritis...  
     psoriatic arthritis; interleukin-21 receptor agonists and antagonists  
     for treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Proteins...  
     p38, inhibitors; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Tumor necrosis factor receptors...  
     p55 and p75; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Connective tissue,disease...  
     scleroderma; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Molecules...  
     small; interleukin-21 receptor agonists and antagonists for treating  
     transplant rejection, autoimmune diseases, cancers and infections  
 Animal tissue,disease...  
     soft, neoplasm; interleukin-21 receptor agonists and antagonists for  
     treating transplant rejection, autoimmune diseases, cancers and  
     infections  
 Neoplasm...  
     solid; interleukin-21 receptor agonists and antagonists for treating

transplant rejection, autoimmune diseases, cancers and infections

Lupus erythematosus...

systemic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Infection...

therapy; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Vaccines...

tumor; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antigens...

tumor-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antigens...

tumor-assocd., RAGE; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antitumor agents...

vaccines; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Blood vessel,disease...

vasculitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Infection...

viral; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

CAS REGISTRY NUMBERS:

542817-54-9P 542817-58-3P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

9001-84-7 329900-75-6 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

59-05-2 53123-88-9 75706-12-6 83869-56-1 140281-74-9 162635-04-3 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

542817-53-8P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

542817-52-7DP 542817-56-1DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

542817-51-6DP 542817-55-0DP 542817-57-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

542820-51-9 542820-52-0 542820-53-1 542820-55-3 542820-56-4 542820-57-5 542820-58-6 542820-59-7 542820-60-0 542820-62-2 542820-64-4 542820-66-6 542820-68-8 542820-70-2 542820-72-4 542820-74-6 542820-76-8 542820-78-0 542820-79-1 542820-80-4 unclaimed nucleotide sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses

542820-50-8 542820-54-2 542820-61-1 542820-63-3 542820-65-5 542820-67-7 542820-69-9 542820-71-3 542820-73-5 542820-75-7 542820-77-9 unclaimed protein sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses

138831-86-4 219312-69-3 434283-61-1 510729-85-8 unclaimed sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses

14/7/8 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2003 American Chemical Society. All rts. reserv.

138302654 CA: 138(20)302654p PATENT

Interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

INVENTOR(AUTHOR): Carter, Laura; Whitters, Matthew J.; Collins, Mary; Young, Deborah A.; Larsen, Glenn; Donaldson, Debra D.; Lowe, Leslie D.; Dunussi, Kyri; Ma, Margery; Witek, Joann S.; Kasaian, Marion T.; Ungar, Michelle

LOCATION: USA

ASSIGNEE: Wyeth, John, and Brother Ltd.

PATENT: PCT International ; WO 200328630 A2 DATE: 20030410

APPLICATION: WO 2002US29839 (20021004) \*US 972218 (20011004) \*US PV373746 (20020417)

PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215005 Immunochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

CA263XXX Pharmaceuticals

IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant immunostimulant transplant rejection, autoimmune disease cancer infection soluble IL21 receptor agonist antagonist

DESCRIPTORS:

Immunostimulants...

adjuvants; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Tumor necrosis factors... Interleukin 12... Interleukin 15... Interleukin 17... Interleukin 18...

agonists and antagonists; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Spinal column,disease...

ankylosing spondylitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

CD4 (antigen)... CD22 (antigen)...

antibodies; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Cytotoxic agents...

antimetabolites; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Dermatitis...

atopic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Thyroid gland,disease...

autoimmune thyroiditis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

A1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

A2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Infection...

bacterial; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Estrogen receptors...

.beta. agonist; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...

carriers; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...

chimeric; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Intestine,disease...

Crohn's; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

D; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

B cell(lymphocyte)...

depletion; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

E; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Lymphocyte...

effector cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Protein motifs...

extracellular domain; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

fragments; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G2a; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G3; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...

G4; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...

humanized; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Disease, animal...  
immune cell-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
immunoconjugates; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...  
immunotoxins; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Intestine, disease...  
inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Cytokines... Enzymes, biological studies...  
inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Diabetes mellitus...  
insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunosuppressants... Lymphocyte... T cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell... B cell(lymphocyte)... Macrophage...  
Megakaryocyte... Transplant rejection... Autoimmune disease... Antigens...  
Vaccines... Immunostimulants... Antitumor agents... Infection... Parasite...  
... Immunotherapy... Multiple sclerosis... Arthritis... Rheumatoid arthritis... Myasthenia gravis... Dermatitis... Eczema... Psoriasis...  
Asthma... Allergy... Antibodies... Immunoglobulins... Toxins...  
Radionuclides, biological studies... Lymphoma... Leukemia... Parasitic worm...  
... Bacterium(genus)... Drugs... Growth inhibitors, animal...  
Anti-inflammatory agents... Cytotoxic agents... Human... Fusion proteins(chimeric proteins)... Osteoarthritis... Mammalia... Immunoglobulin receptors... Molecular cloning... DNA sequences... Protein sequences...  
Protozoa... Genetic vectors... Animal tissue culture... Immunoglobulin receptors...  
interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Rheumatoid arthritis...  
juvenile; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Immunoglobulins...  
M; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Honeybee...  
mellitin signal peptide from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

T cell(lymphocyte)...  
memory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...  
monoclonal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Mouse... Rodentia...  
MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Lymphocyte...

natural killer cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antibodies...

neutralizing; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Transcription factors...

NF- $\kappa$ B (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancer

Anti-inflammatory agents...

nonsteroidal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Selectins...

P-, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Glycoproteins...

PSGL-1 (P-selectin glycoprotein ligand-1), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Arthritis...

psoriatic arthritis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Proteins...

p38, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Tumor necrosis factor receptors...

p55 and p75; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Connective tissue,disease...

scleroderma; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Molecules...

small; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Animal tissue,disease...

soft, neoplasm; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Neoplasm...

solid; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Lupus erythematosus...

systemic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Vaccines...

tumor; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antigens...

tumor-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antigens...

tumor-assocd., RAGE; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antitumor agents...

vaccines; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Blood vessel,disease...  
 vasculitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Infection...  
 viral; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Interleukins... Interleukin receptors...  
 21; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Interleukins...  
 22; agonists and antagonists; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

CAS REGISTRY NUMBERS:

434283-61-1 amino acid sequence, signal peptide, included in fusion protein; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510729-85-8 amino acid sequence, STAT docking site, STAT5; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510788-28-0P 510787-86-7P 510788-32-6P 510788-34-8P 510788-36-0P 510788-38-2P 510788-40-6P 510788-42-8P 510788-44-0P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

329900-75-6 9001-84-7 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

59-05-2 75706-12-6 53123-88-9 162635-04-3 83869-56-1 185243-69-0 140281-74-9 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510787-85-6P 510788-27-9P 510788-31-5P 510788-33-7P 510788-35-9P 510788-37-1P 510788-39-3P 510788-41-7P 510788-43-9P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510787-80-1DP 510787-84-5DP 510787-82-3DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510786-18-2DP 510787-83-4DP 510787-81-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510792-63-9 510792-64-0 510792-65-1 510792-70-8 510792-71-9 510792-72-0 510792-73-1 510792-74-2 510792-75-3 510792-78-6 510792-79-7 510792-80-0 unclaimed nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510792-62-8 510792-66-2 510792-76-4 219312-69-3 138831-86-4 unclaimed protein sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

510792-81-1 510792-82-2 unclaimed sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

14/7/9 (Item 3 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136166068 CA: 136(11)166068e PATENT  
Human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
INVENTOR(AUTHOR): Dumoutier, Laure; Renauld, Jean-Christophe  
LOCATION: USA  
ASSIGNEE: Ludwig Institute for Cancer Research  
PATENT: PCT International ; WO 200210393 A2 DATE: 20020207  
APPLICATION: WO 2001US20485 (20010627) \*US 626617 (20000727)  
PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/24A; C12N-015/63B; C07K-014/54B; G01N-033/50B DESIGNATED COUNTRIES: AU; BR; CA; CN; JP DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE ; IT; LU; MC; NL; PT; SE; TR  
SECTION:  
CA215005 Immunochemistry  
IDENTIFIERS: sequence interleukin 21 gene human, transcription factor  
STAT induction IL21 human mouse, activation transcription interleukin 21 human  
DESCRIPTORS:  
Transcriptional regulation...  
activation; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Proteins...  
acute-phase, induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Gene, animal...  
encoding IL-21; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Thymus gland... Brain...  
expression of IL-21 in mouse; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
B cell(lymphocyte)...  
expression of IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
T cell(lymphocyte)...  
helper cell, IL-9 upregulated IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Liver...  
hepatocyte; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Liver, neoplasm...  
hepatoma, induction of STAT in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Human... cDNA sequences... DNA sequences... Genetic mapping... Mammalia...  
Drug screening... Mouse...  
human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Chromosome...  
human 12, q15; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Mast cell...  
IL-9 upregulated IL-21 in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Lipopolysaccharides...  
induction of IL-21 with; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Haptoglobin...  
induction of; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Kidney...  
mesangium, melanoam, induction of STAT in; human T cell inducible factors, interleukin-21, sequences, chromosomal mapping, and function studies  
Nerve...  
neuron, melanoam, induction of STAT in; human T cell inducible factors,



interleukin-21, sequences, chromosomal mapping, and function studies  
Antibodies...  
of IL-10R.beta.; human T cell inducible factors, interleukin-21,  
sequences, chromosomal mapping, and function studies  
Interleukin 10...  
R.beta.; human T cell inducible factors, interleukin-21, sequences,  
chromosomal mapping, and function studies  
Proteins...  
SAA (serum amyloid A), induction of; human T cell inducible factors,  
interleukin-21, sequences, chromosomal mapping, and function studies  
Transcription factors...  
STAT, induction of; human T cell inducible factors, interleukin-21,  
sequences, chromosomal mapping, and function studies  
Transcription factors...  
STAT1, induction of; human T cell inducible factors, interleukin-21,  
sequences, chromosomal mapping, and function studies  
Transcription factors...  
STAT3, induction of; human T cell inducible factors, interleukin-21,  
sequences, chromosomal mapping, and function studies  
Transcription factors...  
STAT5, induction of; human T cell inducible factors, interleukin-21,  
sequences, chromosomal mapping, and function studies  
Interleukin 4...  
upregulation of IL-21 in TS1 cell with; human T cell inducible factors,  
interleukin-21, sequences, chromosomal mapping, and function studies  
Interleukin 9...  
upregulation of IL-21 with; human T cell inducible factors,  
interleukin-21, sequences, chromosomal mapping, and function studies  
Interleukins...  
21.alpha.; human T cell inducible factors, interleukin-21, sequences,  
chromosomal mapping, and function studies  
Interleukins...  
21.beta.; human T cell inducible factors, interleukin-21, sequences,  
chromosomal mapping, and function studies  
Interleukins...  
21; human T cell inducible factors, interleukin-21, sequences,  
chromosomal mapping, and function studies  
CAS REGISTRY NUMBERS:  
9004-07-3 .alpha.1-chymotrypsin, induction of; human T cell inducible  
factors, interleukin-21, sequences, chromosomal mapping, and function  
studies  
394754-56-4 394754-57-5 nucleotide sequence; human T cell inducible  
factors, interleukin-21, sequences, chromosomal mapping, and function  
studies  
394754-66-6 394754-67-7 394754-68-8 394754-69-9 394754-70-2  
394754-71-3 394754-72-4 394754-73-5 394754-74-6 394754-75-7  
394754-76-8 394754-77-9 394754-78-0 394754-79-1 394754-80-4  
394754-81-5 394754-82-6 394754-83-7 394754-84-8 394754-85-9  
394754-86-0 394754-87-1 394754-88-2 394754-89-3 394754-90-6  
394754-91-7 394754-92-8 394754-93-9 394754-94-0 394754-95-1  
394754-96-2 394754-97-3 394754-98-4 394754-99-5 394755-02-3  
unclaimed nucleotide sequence; human T cell inducible factors,  
interleukin-21, sequences, chromosomal mapping, and function studies  
394755-00-1 394755-01-2 394755-03-4 unclaimed protein sequence; human T  
cell inducible factors, interleukin-21, sequences, chromosomal mapping,  
and function studies  
11028-71-0 upregulation of IL-2 with; human T cell inducible factors,  
interleukin-21, sequences, chromosomal mapping, and function studies

135271906 CA: 135(19)271906d PATENT  
Human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
INVENTOR(AUTHOR): Ebner, Reinhard; Ruben, Steven M.  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20010023070 A1 DATE: 20010920  
APPLICATION: US 731816 (20001208) \*US PV87340 (19980529) \*US PV131965 (19990430) \*US 320713 (19990527) \*WO 99US11644 (19990527) \*US PV169837 (19991209)  
PAGES: 87 pp., Cont.-in-part of U.S. Ser. No. 320,713. CODEN: USXXCO  
LANGUAGE: English CLASS: 435069500; C12P-021/02A; C12Q-001/68B; G01N-033/53B; C07H-021/04B; C12N-005/06B  
SECTION:  
CA215005 Immunochemistry  
CA201XXX Pharmacology  
CA203XXX Biochemical Genetics  
IDENTIFIERS: sequence human interleukin 21 22 cDNA  
DESCRIPTORS:  
Gene, animal...  
for interleukins-21 or -22; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
Protein sequences... cDNA sequences...  
human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
Interleukins...  
interleukin-21; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
Interleukins...  
interleukin-22; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
Molecular cloning...  
of interleukin-21 and -22 nucleic acids; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
Antibodies...  
to interleukins-21 and -22; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
CAS REGISTRY NUMBERS:  
251639-93-7P 251639-95-9P 251100-02-4P amino acid sequence; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-73-3 interleukin 21 domain I-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-74-4 interleukin 21 domain II-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-80-2 interleukin 21 domain III-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-81-3 interleukin 21 domain IV-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-86-8 interleukin 21 domain V-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-87-9 interleukin 21 domain VI-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-88-0 interleukin 21 domain VII-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-82-4 interleukin 22 domain I-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-83-5 interleukin 22 domain II-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-84-6 interleukin 22 domain III-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-85-7 interleukin 22 domain IV-encoding cDNA; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
251639-89-1 251639-94-8 251639-97-1 nucleotide sequence; human interleukin-21 and -22 and cDNAs and their use in diagnosis and therapy  
169109-62-0 181380-11-0 251662-03-0 251662-04-1 251662-20-1

251662-26-7 362647-78-7 362677-50-7 133198-29-5 215663-51-7  
244008-08-0 244008-09-1 244008-12-6 244008-13-7 unclaimed sequence;  
human interleukin-21 and -22 and cDNAs and their use in diagnosis and  
therapy

251662-46-1 251662-45-0 Unclaimed; human interleukin-21 and -22 and cDNAs  
and their use in diagnosis and therapy

Set	Items	Description
S1	89	E5-E12
S2	25	S1 AND (T(W)CELL(W)INDUCIBLE OR TIF?)
S3	13	RD S2 (unique items)
S4	7377	(T(W)CELL(W)INDUCIBLE OR TIF?)
S5	7	(T(W)CELL(W)INDUCIBLE(W)FACTOR?)
S6	5	RD S5 (unique items)
S7	132	IL(W)21
S8	73	RD S7 (unique items)
S9	13	S8 AND PY<2000
S10	13	RD S9 (unique items)
S11	141	INTERLEUKIN(W)21
S12	75	RD S11 (unique items)
S13	10	INTERLEUKIN(W)21(20N) (NUCLEIC OR DNA)
S14	10	RD S13 (unique items)
?		